Work

PD-L1 status and clinical outcomes to cabozantinib, sunitinib and everolimus in patients with metastatic clear-cell RCC treated on CABOSUN and METEOR clinical trials

Year: 2018

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdy424.040

Authors: T.K. Choueiri, A. Flaifel, W. Xie, D. Braun, M. Ficial, R. Jennings, A. Nassar, B. Escudier, D.J. George, R.J. Motzer, M.J. Morris, T. Powles, E. Wang, Y. Huang, G. Freeman, S. Signoretti

Institutions: Dana-Farber Cancer Institute, Brigham and Women's Hospital, Institut Gustave Roussy, Duke Medical Center, Memorial Sloan Kettering Cancer Center, Barts Cancer Institute, Exelixis (United States)

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Pfizer, AstraZeneca, Exelixis

OpenAlex ID: W2898219094

FWCI:

Cites:

Cited by:

Related to: 10